111 related articles for article (PubMed ID: 21778315)
1. Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer.
Fotopoulou C; Sehouli J; Pschowski R; VON Haehling S; Domanska G; Braicu EI; Fusch G; Reinke P; Schefold JC
Anticancer Res; 2011 Aug; 31(8):2629-35. PubMed ID: 21778315
[TBL] [Abstract][Full Text] [Related]
2. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
[TBL] [Abstract][Full Text] [Related]
3. Influence of core body temperature on Tryptophan metabolism, kynurenines, and estimated IDO activity in critically ill patients receiving target temperature management following cardiac arrest.
Schefold JC; Fritschi N; Fusch G; Bahonjic A; Doehner W; von Haehling S; Pschowski R; Storm C; Schroeder T
Resuscitation; 2016 Oct; 107():107-14. PubMed ID: 27565863
[TBL] [Abstract][Full Text] [Related]
4. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
5. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis.
Changsirivathanathamrong D; Wang Y; Rajbhandari D; Maghzal GJ; Mak WM; Woolfe C; Duflou J; Gebski V; dos Remedios CG; Celermajer DS; Stocker R
Crit Care Med; 2011 Dec; 39(12):2678-83. PubMed ID: 21765346
[TBL] [Abstract][Full Text] [Related]
6. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
Schefold JC; Zeden JP; Pschowski R; Hammoud B; Fotopoulou C; Hasper D; Fusch G; Von Haehling S; Volk HD; Meisel C; Schütt C; Reinke P
Scand J Infect Dis; 2010 Mar; 42(3):164-71. PubMed ID: 19958238
[TBL] [Abstract][Full Text] [Related]
7. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy.
von Bubnoff D; Bieber T
Allergy; 2012 Jun; 67(6):718-25. PubMed ID: 22519427
[TBL] [Abstract][Full Text] [Related]
8. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.
Berthon C; Fontenay M; Corm S; Briche I; Allorge D; Hennart B; Lhermitte M; Quesnel B
Leuk Res; 2013 May; 37(5):573-9. PubMed ID: 23453284
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity.
Hoshi M; Ito H; Fujigaki H; Takemura M; Takahashi T; Tomita E; Ohyama M; Tanaka R; Saito K; Seishima M
Leuk Res; 2009 Jan; 33(1):39-45. PubMed ID: 18639341
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.
Ball HJ; Yuasa HJ; Austin CJ; Weiser S; Hunt NH
Int J Biochem Cell Biol; 2009 Mar; 41(3):467-71. PubMed ID: 18282734
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.
Inaba T; Ino K; Kajiyama H; Shibata K; Yamamoto E; Kondo S; Umezu T; Nawa A; Takikawa O; Kikkawa F
Gynecol Oncol; 2010 Jun; 117(3):423-8. PubMed ID: 20350764
[TBL] [Abstract][Full Text] [Related]
12. Molecules in focus: indoleamine 2,3-dioxygenase.
King NJ; Thomas SR
Int J Biochem Cell Biol; 2007; 39(12):2167-72. PubMed ID: 17320464
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality.
Pertovaara M; Raitala A; Lehtimäki T; Karhunen PJ; Oja SS; Jylhä M; Hervonen A; Hurme M
Mech Ageing Dev; 2006 May; 127(5):497-9. PubMed ID: 16513157
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes.
Belladonna ML; Puccetti P; Orabona C; Fallarino F; Vacca C; Volpi C; Gizzi S; Pallotta MT; Fioretti MC; Grohmann U
Transplantation; 2007 Jul; 84(1 Suppl):S17-20. PubMed ID: 17632406
[TBL] [Abstract][Full Text] [Related]
15. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
16. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study.
Niinisalo P; Oksala N; Levula M; Pelto-Huikko M; Järvinen O; Salenius JP; Kytömäki L; Soini JT; Kähönen M; Laaksonen R; Hurme M; Lehtimäki T
Ann Med; 2010; 42(1):55-63. PubMed ID: 19941414
[TBL] [Abstract][Full Text] [Related]
17. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism.
Takikawa O
Biochem Biophys Res Commun; 2005 Dec; 338(1):12-9. PubMed ID: 16176799
[TBL] [Abstract][Full Text] [Related]
19. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
20. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
